Hana Pharm Co Ltd Asset Resilience Ratio
Hana Pharm Co Ltd asset resilience ratio. Hana Pharm Co Ltd (293480) has an Asset Resilience Ratio of 1.10% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Hana Pharm Co Ltd (293480) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Hana Pharm Co Ltd (2016–2025)
Asset resilience ratio of Hana Pharm Co Ltd from 2016 to 2025. This chart shows how Hana Pharm Co Ltd's Asset Resilience Ratio has changed over time. Read debt load of Hana Pharm Co Ltd for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Hana Pharm Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 293480 total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩4.91 Billion | 1.1% |
| Total Liquid Assets | ₩4.91 Billion | 1.10% |
Asset Resilience Insights
- Limited Liquidity: Hana Pharm Co Ltd maintains only 1.10% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hana Pharm Co Ltd Industry Peers by Asset Resilience Ratio
Compare Hana Pharm Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Hana Pharm Co Ltd Asset Resilience Ratio by Year (2016–2025)
Hana Pharm Co Ltd asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for Hana Pharm Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.87% | ₩3.63 Billion ≈ $2.46 Million |
₩418.14 Billion ≈ $283.37 Million |
-0.08pp |
| 2024-12-31 | 0.95% | ₩3.64 Billion ≈ $2.47 Million |
₩382.01 Billion ≈ $258.88 Million |
-0.41pp |
| 2023-12-31 | 1.36% | ₩4.73 Billion ≈ $3.21 Million |
₩348.39 Billion ≈ $236.10 Million |
-0.10pp |
| 2022-12-31 | 1.46% | ₩5.03 Billion ≈ $3.41 Million |
₩345.96 Billion ≈ $234.46 Million |
-15.10pp |
| 2021-12-31 | 16.56% | ₩50.25 Billion ≈ $34.05 Million |
₩303.50 Billion ≈ $205.68 Million |
-2.54pp |
| 2020-12-31 | 19.10% | ₩52.83 Billion ≈ $35.80 Million |
₩276.58 Billion ≈ $187.43 Million |
-9.19pp |
| 2019-12-31 | 28.29% | ₩74.42 Billion ≈ $50.44 Million |
₩263.03 Billion ≈ $178.25 Million |
-8.56pp |
| 2018-12-31 | 36.85% | ₩89.32 Billion ≈ $60.53 Million |
₩242.38 Billion ≈ $164.26 Million |
+34.34pp |
| 2017-12-31 | 2.51% | ₩3.55 Billion ≈ $2.41 Million |
₩141.55 Billion ≈ $95.93 Million |
+0.96pp |
| 2016-12-31 | 1.54% | ₩1.77 Billion ≈ $1.20 Million |
₩114.59 Billion ≈ $77.66 Million |
-- |
About Hana Pharm Co Ltd
Hana Pharm Co., Ltd. develops and provides various pharmaceutical products in South Korea and internationally. It offers anesthetics, narcotic analgesics, antiemetics, muscle relaxants, cardiovascular and endocrine system, gastrointestinal system, respiratory system, antibiotics, dermatology, urinology, osteoporosis, and central nervous system products, as well as analgesics, antipyretics, and an… Read more